Gabapentin
Gralise, Neurontin (gabapentin) is a small molecule pharmaceutical. Gabapentin was first approved as Neurontin on 1993-12-30. It is used to treat bipolar disorder, epilepsy, partial epilepsies, phobic disorders, and postherpetic neuralgia in the USA. It is known to target potassium voltage-gated channel subfamily KQT member 3 and potassium voltage-gated channel subfamily KQT member 5.
Download report
Favorite
Top Prescription Drugs
Commercial
Trade Name
FDA
EMA
Gralise, Neurontin (generic drugs available since 2003-09-12)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| gabapentin | ANDA | 2023-06-20 |
| gralise | New Drug Application | 2023-03-01 |
| neurontin | New Drug Application | 2021-10-01 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| bipolar disorder | EFO_0000289 | D001714 | F30.9 |
| epilepsy | EFO_0000474 | D004827 | G40.9 |
| partial epilepsies | EFO_0004263 | D004828 | — |
| phobic disorders | EFO_1001908 | D010698 | F40 |
| postherpetic neuralgia | — | D051474 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Gabapentin, Gralise, Almatica | |||
| 7438927 | 2024-02-26 | U-1114 | |
HCPCS
No data
Clinical
Clinical Trials
384 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Postoperative pain | D010149 | G89.18 | 7 | 3 | 9 | 22 | 9 | 48 | |
| Pain | D010146 | EFO_0003843 | R52 | 2 | 3 | 5 | 14 | 10 | 32 |
| Healthy volunteers/patients | — | 9 | — | 1 | 1 | 7 | 18 | ||
| Sleep initiation and maintenance disorders | D007319 | F51.01 | 1 | 4 | 8 | 1 | 1 | 15 | |
| Hot flashes | D019584 | — | 2 | 7 | 1 | 4 | 14 | ||
| Neuralgia | D009437 | EFO_0009430 | 1 | 4 | 1 | 3 | 4 | 13 | |
| Alcoholism | D000437 | EFO_0003829 | F10.1 | — | 8 | 3 | 1 | 1 | 11 |
| Diabetic neuropathies | D003929 | EFO_1000783 | — | 2 | 1 | 8 | — | 11 | |
| Chronic pain | D059350 | HP_0012532 | — | 4 | 3 | 1 | 2 | 10 | |
| Restless legs syndrome | D012148 | EFO_0004270 | G25.81 | 1 | 1 | 1 | 4 | 2 | 9 |
Show 73 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 2 | 4 | — | 3 | 8 |
| Neoplasms | D009369 | C80 | — | 2 | 1 | — | 2 | 5 | |
| Depression | D003863 | F33.9 | — | 1 | 1 | — | 2 | 4 | |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | — | 1 | 2 | — | 2 | 4 |
| Pruritus | D011537 | HP_0000989 | L29 | 1 | — | 1 | — | 2 | 4 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | 1 | 2 | 1 | — | — | 3 |
| Postoperative complications | D011183 | — | 1 | 1 | — | 1 | 3 | ||
| Vomiting | D014839 | HP_0002013 | R11.1 | — | — | 3 | — | — | 3 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | 1 | 1 | — | 1 | 3 |
| Menopause | D008593 | EFO_0003922 | N95 | — | 1 | 1 | — | 1 | 3 |
Show 35 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | 3 | — | — | — | 3 |
| Psychotic disorders | D011618 | F20.81 | 1 | 2 | — | — | — | 2 | |
| Marijuana abuse | D002189 | EFO_0007191 | F12 | — | 2 | — | — | — | 2 |
| Male breast neoplasms | D018567 | — | 1 | — | — | — | 1 | ||
| Anxiety | D001007 | EFO_0005230 | F41.1 | 1 | 1 | — | — | — | 1 |
| Spontaneous abortion | D000022 | EFO_1001255 | O00.1 | — | 1 | — | — | — | 1 |
| Fabry disease | D000795 | E75.21 | — | 1 | — | — | — | 1 | |
| Cocaine-related disorders | D019970 | F14 | — | 1 | — | — | — | 1 | |
| Intervertebral disc displacement | D007405 | EFO_1001800 | — | 1 | — | — | — | 1 | |
| Mood disorders | D019964 | EFO_0004247 | F30-F39 | — | 1 | — | — | — | 1 |
Show 15 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stomatitis | D013280 | EFO_1001904 | K12.1 | 1 | — | — | — | — | 1 |
| Squamous cell carcinoma of head and neck | D000077195 | 1 | — | — | — | — | 1 | ||
| Weight loss | D015431 | HP_0001824 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vulvodynia | D056650 | N94.81 | — | — | — | — | 2 | 2 | |
| Renal cell carcinoma | D002292 | — | — | — | — | 2 | 2 | ||
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | — | — | — | — | 2 | 2 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | — | — | — | — | 2 | 2 |
| Chronic pancreatitis | D050500 | EFO_0000342 | K86.1 | — | — | — | — | 2 | 2 |
| Pelvic neoplasms | D010386 | — | — | — | — | 2 | 2 | ||
| Aortic valve disease | D000082862 | — | — | — | — | 1 | 1 | ||
| Coronary artery disease | D003324 | I25.1 | — | — | — | — | 1 | 1 | |
| Spinal fusion | D013123 | — | — | — | — | 1 | 1 | ||
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | — | — | 1 | 1 |
Show 27 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | GABAPENTIN |
| INN | gabapentin |
| Description | Gabapentin is a gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome. It has a role as an anticonvulsant, a calcium channel blocker, an environmental contaminant and a xenobiotic. It is functionally related to a gamma-aminobutyric acid. |
| Classification | Small molecule |
| Drug class | gabamimetics |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | NCC1(CC(=O)O)CCCCC1 |
Identifiers
| PDB | — |
| CAS-ID | 60142-96-3 |
| RxCUI | 25480 |
| ChEMBL ID | CHEMBL940 |
| ChEBI ID | 42797 |
| PubChem CID | 3446 |
| DrugBank | DB00996 |
| UNII ID | 6CW7F3G59X (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
KCNQ3
KCNQ3
KCNQ5
KCNQ5
Organism
Homo sapiens
Gene name
KCNQ3
Gene synonyms
NCBI Gene ID
Protein name
potassium voltage-gated channel subfamily KQT member 3
Protein synonyms
KQT-like 3, Potassium channel subunit alpha KvLQT3, potassium channel, voltage gated KQT-like subfamily Q, member 3, potassium channel, voltage-gated, subfamily Q, member 3, potassium voltage-gated channel, KQT-like subfamily, member 3, Voltage-gated potassium channel subunit Kv7.3
Uniprot ID
Mouse ortholog
Kcnq3 (110862)
potassium voltage-gated channel subfamily KQT member 3 (Q8K3F6)
Variants
Clinical Variant
No data
Financial
Gralise - Assertio Therapeutics
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Gralise - Assertio Therapeutics
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Neurontin - Pfizer
$
€
£
₣
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 24,267 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
50,486 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more